Do Interleukin-1 and Interleukin-6 Antagonists Hold Any Place in the Treatment of Atherosclerotic Cardiovascular Disease and Related Co-Morbidities? An Overview of Available Clinical Evidence.

J Clin Med · 2023 · PMC9962740 · PMID 36835838

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

marginally non-significantno p-value reported

Another relevant meta-analysis showed that tocilizumab might decrease the risk for MACE in patients with RA, compared to tumor necrosis factor inhibitors, with the result being marginally non-significant [ 65 ].

also in 1,493 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.